AQR Capital Management
CUE icon

AQR Capital Management’s Cue Biopharma CUE Stock Holding History

AQR Capital Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-745
Closed -$59K – 2433
2023
Q4 		$59K Sell
745
-51
-6% -$3.65K ﹤0.01% 2303
2023
Q3 		$54.9K Buy
+796
New +$77.7K ﹤0.01% 2280
2021
Q1 		– Sell
-1,043
Closed -$391K – 2201
2020
Q4 		$391K Sell
1,043
-186
-15% -$74.3K ﹤0.01% 1872
2020
Q3 		$555K Buy
1,229
+515
+72% +$297K ﹤0.01% 1680
2020
Q2 		$525K Sell
714
-17
-2% -$12.3K ﹤0.01% 1724
2020
Q1 		$311K Buy
+731
New +$354K ﹤0.01% 1754

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management's CUE Position: Q1 2024 in Review

AQR Capital Management sold out of Cue Biopharma (CUE) in Q1 2024, closing a stake of 745 shares — an estimated $59K sold.

AQR Capital Management first reported a position in CUE in Q1 2020 and held it in 6 quarters. The position peaked at $555K in Q3 2020. 74 funds tracked by Wall St. Rank hold CUE as of Q1 2024.

  • AQR Capital Management reported no remaining Cue Biopharma position as of Q1 2024 after selling out during the quarter.
  • AQR Capital Management sold 745 Cue Biopharma shares in Q1 2024, an estimated $59K.
  • AQR Capital Management first reported a position in Cue Biopharma in Q1 2020 and held it in 6 quarters.
  • AQR Capital Management's Cue Biopharma position peaked at $555K in Q3 2020.
  • 74 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2024.

Based on AQR Capital Management's 13F filing for Q1 2024, filed 15 May 2024.